We suggest you to use BioLight Life Sciences fundamental analysis to find out if markets are presently mispricing the company. In plain English you can use it to find out if BioLight Life Sciences is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We found twenty-eight available fundamental indicators for BioLight Life Sciences Ltd which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all BioLight Life Sciences fundamentals including its Price to Book, Revenue, EBITDA, as well as the relationship between Price to Sales and Gross Profit .
BioLight Life Company Summary
BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions comprising glaucoma, dry eye syndrome, and age-related macular degeneration. BioLight Life Sciences Ltd. was founded in 2005 and is based in Tel Aviv, Israel. BioLight Life operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.
BioLight Life Beta vs Earnings Per Share
BioLight Life Sciences Ltd is number one stock in beta category among related companies. It is number one stock in earnings per share category among related companies creating about 45.44 of Earnings Per Share per Beta.
|Earnings Per Share ( times )|
BioLight Life Market Fundamentals